Fremont, CA, Mar 22, 2011 (JCN Newswire) - Quark Pharmaceuticals, an investee company of the SBI Group’s funds with 35.82% shareholding, announced press release as below regarding progress of clinical test of PF-04523655 (RTP801I-14), its drug pipeline.
